Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00853645
Other study ID # DN-11398
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2008
Est. completion date September 2008

Study information

Verified date July 2021
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective is to evaluate the safety and performance of the implanted Subcutaneous implantable cardioverter defibrillator (S-ICD) system. A maximum of 10 subjects were to be enrolled and followed for one month to collect data on the safety, efficacy, and performance of the implanted S-ICD system. Additionally, patient comfort will be assessed as will cosmetic outcome.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - replacement of an existing transvenous implantable cardioverter defibrillator (ICD) system - American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) Class I or II indications for ICD implantation - Age >= 18 years - Appropriate pre-operative Electrocardiogram (ECG) as measured with a specially developed template Exclusion Criteria: - Subjects unable or unwilling to provide informed consent - Any condition which precludes the subject's ability to comply with the study requirements - Females who are pregnant or lactating and pre-menopausal women who are unwilling to use adequate birth control for the duration of the study - Participation in another investigational device trial at any time during the conduct of the S-ICD system trial without written consent from the sponsor. - Patients with a serious medical condition and life expectancy of less than one year. - Patients with documented spontaneous and frequently recurring ventricular tachyarrhythmias (VT) that is reliably terminated with anti-tachycardia pacing - Patients with existing epicardial patches or subcutaneous electrodes in the left thoracic quadrant - Patients with chronic renal failure, i.e. with a creatinine level of >2.5 mg/dl unless prescribed drug therapy known to increase creatinine levels in which case the value should be <= 3mg/dl

Study Design


Intervention

Device:
Subcutaneous Implantable Defibrillator (S-ICD) System


Locations

Country Name City State
New Zealand Auckland City Hospital Auckland
New Zealand Christchurch Hospital Christchurch

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a Successful Induced Ventricular Fibrillation Conversion Sustained ventricular fibrillation induced by the investigator is successfully converted. A successful conversion was defined as two consecutive successful shocks out of four attempts with either standard polarity or with reverse polarity. 30 days
See also
  Status Clinical Trial Phase
Withdrawn NCT05084391 - Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART) Phase 1/Phase 2
Completed NCT01492764 - Ablation of Ventricular Fibrillation by Accurate Targeting of Arrhythmogenic Regions (AVATAR)
Completed NCT01906775 - Sub-threshold Pacing to Prevent Pacemaker-induced Ventricular Tachycardia N/A